Financial Data and Key Metrics Changes - Revenue for Q4 2025 was $10,000, down from $24,000 in Q4 2024, reflecting modest revenue fluctuations typical in early commercial stages [19] - Total revenue for 2025 was $81,000, a slight increase from $77,000 in 2024, indicating gradual revenue growth [21] - Operating expenses for Q4 2025 were $9 million, down from $9.4 million in the prior year, showcasing disciplined expense management [19] - Net loss for Q4 2025 was $7.9 million compared to a net loss of $8.6 million in Q4 2024, demonstrating improved financial performance [21] Business Line Data and Key Metrics Changes - Research and development expenses for 2025 were $13.2 million, down from $14.7 million in 2024, as resources shifted towards commercialization [21] - Selling, general, and administrative expenses were $23.3 million in 2025, up from $21.9 million in 2024, due to targeted commercial readiness investments [21] Market Data and Key Metrics Changes - The company engaged with 13 states for partner programs, exceeding its initial goal of six states, and aims to expand to 15-17 states by year-end 2026 [8] - In Europe, the company is advancing its regulatory pathway for the preterm global test and is on track to submit European dossiers in the coming months [9] Company Strategy and Development Direction - The company aims to build evidence, access, and commercial infrastructure to drive preterm birth adoption at scale, with a focus on Medicaid and high preterm birth burden states [5] - The strategy includes launching targeted programs to generate outcomes data that support clinical adoption and reimbursement expansion [7] - The company plans to maintain disciplined investments in market access and commercial infrastructure while expanding geographically [10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the momentum gained from the PRIME publication and the growing engagement with payers and states [45] - The focus for 2026 will be on disciplined execution, advancing partner programs, and supporting clinicians in integrating PreTRM into workflows [45] - The company believes that compelling clinical evidence and increasing payer engagement will unlock significant value in an underserved market [45] Other Important Information - The company ended 2025 with $95.8 million in cash equivalents, providing a runway through 2028 for significant adoption and commercial milestones [22] - The capital allocation philosophy emphasizes disciplined deployment towards milestones that de-risk the commercial model while maintaining balance sheet strength [23] Q&A Session Summary Question: Can you expand on converting payer discussions and partner programs using outcomes and economic data? - The company highlighted the importance of clinical outcomes and economic benefits to engage partners, particularly state Medicaid agencies [29] - The reduction in NICU admissions is a significant cost driver for payers, making the economic model compelling [30] Question: What feedback was received at the SMFM conference regarding PRIME? - The conference led to increased engagement with providers and state legislators, with a focus on making the test more accessible [33] - The publication has improved credibility and engagement across various stakeholders [35] Question: How will the company balance investments in successful U.S. states versus global EU launch capital requirements? - The company plans to maintain a similar cash operating expense budget while reallocating spending towards commercial activities, including EU opportunities [39] Question: Can you elaborate on the profile of the new partner in the second partnership program? - The company is negotiating with various partners, including large health systems and provider payers, to implement the PreTRM test as standard care [41] - The second partner is an employer collaborative with multi-state opportunities, showcasing the diverse nature of partnerships [43]

Summary of Sera Prognostics FY Conference Call Company Overview - **Company**: Sera Prognostics (NasdaqGM:SERA) - **Industry**: Healthcare, specifically focusing on maternal-fetal health and preterm birth prevention Key Points Unmet Need for Preterm Birth - Approximately 1 in 10 babies are born prematurely, which is a significant public health issue [4] - There are limited screening options for physicians to assess the risk of preterm birth, leading to high healthcare costs and long-term health complications for premature infants [5] PRIME Trial Insights - The PRIME trial involved 5,000 participants and demonstrated a 20% reduction in NICU admissions and a 56% reduction in births below 32 weeks gestation [7] - The trial showed a statistically significant 20% reduction in neonatal morbidity and mortality, which has garnered positive feedback from clinicians [9] Economic Impact - The lifetime healthcare costs for premature infants can be 50 to 300 times higher than for full-term infants, resulting in societal costs in the tens of billions [5] - The number needed to screen to prevent one NICU day is 4.2, indicating strong health economic potential for the test [12] Commercial Strategy and Expansion - Sera Prognostics is expanding its reach from 3-5 states to 10 states, with plans to engage with additional states and Medicaid programs [18][19] - The company is targeting state Medicaid directors and commercial insurers to demonstrate the economic benefits of their screening test [20] Provider Engagement - The company is working with various types of providers, including physician offices, clinics, and virtual providers, to implement their screening test [22] - There is a focus on educating healthcare providers about the test and its benefits, which will be crucial for adoption [70] Guidelines and Regulatory Path - The company is actively engaging with organizations like the Society for Maternal-Fetal Medicine and ACOG to influence guidelines related to preterm birth prevention [80][81] - The timeline for guideline updates is expected to be gradual, with significant changes taking 3-5 years [85] Financial Outlook - Sera Prognostics has over $100 million in cash, providing a runway for commercial strategy execution over the next three years [103] - The company plans to reallocate funds from R&D to commercial efforts, including doubling the sales team to enhance market penetration [105] International Expansion - Sera Prognostics is also looking to enter the European market, where reimbursement processes may be more straightforward due to single-payer systems [107] Additional Important Insights - The company is seeing a positive response from the healthcare community following the PRIME publication, which is expected to facilitate quicker adoption of their test [20] - The focus on Medicaid is critical as it covers about 50% of births in the U.S., making it a key target for the company's initiatives [37] This summary encapsulates the critical aspects of Sera Prognostics' conference call, highlighting the company's focus on addressing the unmet need for preterm birth screening, the positive outcomes from the PRIME trial, and the strategic plans for commercial expansion and guideline influence.

Core Insights - Preterm birth is viewed as an avoidable high-risk event that can be anticipated and managed proactively, with a focus on earlier detection and standardized care pathways to reduce neonatal harm [1][3] - The PRIME trial demonstrated that a screen-guided approach can significantly reduce NICU admissions and improve neonatal outcomes, emphasizing the importance of proactive, outcomes-driven maternity care [2][3] Company Overview - Hera Women's Health is a national collaborative focused on providing advanced, personalized care for women, emphasizing data-driven, outcome-oriented practices [4] - The company aims to enhance healthcare outcomes by facilitating collaboration between Obstetrics and Maternal Fetal Medicine providers through evidence-based protocols and technology [4] PRIME Trial Findings - The PRIME trial involved 5018 participants across 19 sites and showed a 20% reduction in the composite neonatal morbidity/mortality index and shorter neonatal hospital stays [5] - The screen-guided approach resulted in fewer NICU admissions (10.2% vs 12.8%) and a total of 58 fewer NICU admissions and 545 fewer NICU days in the screen-guided arm [5] Competitive Advantage - Hera Women's Health has achieved a 25% reduction in preterm births and a 40% reduction in cesarean deliveries compared to regional competitors, highlighting its effective approach to maternity care [3]

Financial Data and Key Metrics Changes - Net revenue for Q4 2024 was $24,000, down from $41,000 in Q4 2023 [32] - Total operating expenses for Q4 were $9.4 million, up 6% from $8.9 million in the same period last year [32] - Net loss for the quarter was $8.6 million compared to $7.9 million for the same period a year ago [32] - Cash, cash equivalents, and available-for-sale securities as of December 31, 2024, were approximately $68.2 million [33] Business Line Data and Key Metrics Changes - Research and development expenses decreased to $3.1 million from $3.9 million in Q4 2023, primarily due to reduced expenses related to the PRIME study [32] - Selling, general, and administrative expenses increased to $6.3 million from $5.0 million in Q4 2023, driven by spending on commercial activities [32] Market Data and Key Metrics Changes - The U.S. received a D+ grade from the March of Dimes for high preterm birth rates, indicating a significant market need for solutions [22] - Medicaid covers approximately 43% of births in the U.S., representing a substantial opportunity for the company to reduce costs for public health agencies [24] Company Strategy and Development Direction - The company aims to leverage the results of the PRIME study to drive awareness and adoption of its PreTRM test, focusing on building its evidence portfolio and seeking reimbursement [19][20] - Plans include expanding commercial operations in the U.S. and exploring international opportunities, particularly in Europe [20][26] - The company is focused on generating real-world evidence to support the adoption of its test and treat strategy [44] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the potential for Medicaid to adopt the PreTRM test more quickly due to the current focus on cost reduction and improving clinical outcomes [51] - The company anticipates a pivotal year in 2025 for engagement with key stakeholders and adoption of its test following the publication of the PRIME study [35] Other Important Information - The company raised $57.5 million through a public follow-on offering to expand its commercial operations and secure a cash runway through 2028 [34] - The company is working on two products from its pipeline, targeting launches in the second half of 2025 [76] Q&A Session Summary Question: Can you elaborate on the three tenants of your plan to get into guidelines? - Management discussed plans for publishing more information, providing real-world evidence, and driving clinical community adoption to support the PreTRM test [40][41][46] Question: What are your plans regarding Medicaid and its coverage of the test? - Management highlighted the significant opportunity with Medicaid, emphasizing the potential for cost savings and the importance of focusing on states with high preterm birth rates [48][50][52] Question: How do you view the timeline for getting into guidelines? - Management indicated that while it is difficult to predict, there is potential for updates to guidelines within the next one to three years, especially with the upcoming publication of the PRIME study [61][62] Question: What is the expected cash runway based on current operating plans? - Management stated that the cash runway extends into 2028, with operating expenses projected between $30 million to $35 million for the year [64] Question: What are the commercial investments planned for 2025? - Management outlined plans to build a sales organization, enhance medical liaison efforts, and optimize the revenue cycle to drive adoption of the PreTRM test [70][73]